|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
|
Counterfeiting affects the pharmaceutical sector on a global scale, with the value of counterfeit products traded worldwide estimated to be around €4 billion per year. With the topic high on the agenda for governing bodies and manufacturers alike, some steps have already been taken to introduce anti-counterfeiting measures, such as tracking labels, to make medicines easier to trace and harder to replicate. However, to effectively tackle the challenge the grey market presents, the solution needs to be tamper-proof, cost-effective, and easy to realise on a large scale. This article explores why leveraging radio frequency identification (RFID) technology to improve supply chain visibility and integrity can be key to overcoming the challenge.
The volume of falsified and counterfeit medicines has been increasing steadily. Several factors, including high profit margins, low risk of detection, and weak penalties, make pharmaceutical products an attractive target for criminals. They are also relatively easy to pass onto consumers as authentic products. Regardless of the type of drug, counterfeit products present a serious risk to health and safety, and, in a worst-case scenario, they can cost lives. The practice also has profound financial implications.
It infringes intellectual property rights, damaging pharma manufacturers’ profitability, while EU governments lose around €1.7 billion per year in revenue. Clearly, both manufacturers and governments have a lot to gain by eliminating the issue.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Emmes launches Orphan Reach™: Emmes’ Rare Disease Center
03rd November, 2021, Rockville, Maryland (USA): Emmes – a full service, global clinical research organization (CRO) – is launching its new center, Orphan Reach™ as a unique ‘rare CRO’.
More info >> |
|
 |
White Papers |
 |
|
Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts
Eurofins BioPharma Product Testing
Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >> |
|
|
